MDS research criteria for prodromal Parkinson's disease

Abstract

This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.

Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease

“…Olfactory testing has recently been incorporated in the newly established International Parkinson and Movement Disorder Society criteria for PD6 and prodromal PD 7…”

What the “man in the moon” can tell us about the future of our brains

“…Based on the fact that iRBD diagnosed by polysomnography is by far the most specific prodromal sign of an evolving underlying synuclein disease (33), or even an indication of ongoing α-synuclein disease (4), patients with iRBD are a potentially important target population to study in upcoming trials, not only with substances to alleviate symptoms of RBD (34), but also with potentially diseasemodifying or neuroprotective substances. In addition, the long gap between the onset of iRBD and conversion to neurodegeneration (up to several decades) creates a need to identify subsets of patients who are going to convert in the near future, or who will convert to a more specific endpoint.…”

Parkinson’s Disease- A Review

“…(14), (15) Investigation is going on to identify biomarkers of Parkinson's disease, but that will help in early diagnosis and slow progression of the disease. Agents currently under investigation are anti-apoptotics (Omigapil), anti-glutamatergics, monoamine oxidase inhibitors (Selegiline), promitochondrials (Coenzyme Q10, creatine), calcium channel blockers (Isradipine) and growth factors (GDNF).…”